Author Contributions: Dr Tejpar had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs De Roock, Jonker, and Di Nicolantonio contributed equally to this article. Drs De Roock and Jonker wrote the first draft of the manuscript and were equally involved in study concept and design, clinical data collection, and clinical data analysis. Dr Di Nicolantonio was primarily responsible for all in vitro and in vivo data.
Study concept and design: De Roock, Jonker, Di Nicolantonio, Siena, Bardelli, Tejpar.
Acquisition of data: De Roock, Jonker, Di Nicolantonio, Sartore-Bianchi, Tu, Siena, Lamba, Arena, Van Cutsem, O’Callaghan, Khambata-Ford, Simes, Tejpar.
Analysis and interpretation of data: De Roock, Jonker, Di Nicolantonio, Sartore-Bianchi, Tu, Siena, Lamba, Arena, Frattini, Piessevaux, O’Callaghan, Khambata-Ford, Zalcberg, Simes, Karapetis, Bardelli, Tejpar.
Drafting of the manuscript: De Roock, Jonker, Bardelli, Tejpar.
Critical revision of the manuscript for important intellectual content: De Roock, Jonker, Di Nicolantonio, Sartore-Bianchi, Tu, Siena, Lamba, Arena, Frattini, Piessevaux, Van Cutsem, O’Callaghan, Khambata-Ford, Zalcberg, Simes, Karapetis, Bardelli, Tejpar.
Statistical analysis: De Roock, Jonker, Di Nicolantonio, Tu, Piessevaux, Karapetis, Tejpar.
Obtained funding: Simes, Bardelli, Tejpar.
Administrative, technical, or material support: Khambata-Ford, Tejpar.
Study supervision: Jonker, Bardelli, Tejpar.
Financial Disclosures: Dr Siena reports serving as a member of advisory boards for Merck Serono, Amgen, AstraZeneca, and Celgene. Dr Van Cutsem reports receiving research funding from Merck Serono and Amgen. Dr Khambata-Ford reports owning equity in and is an employee of Bristol-Myers Squibb. Dr Zalcberg reports receiving travel and research support from Merck Serono and research support from Bristol-Myers Squibb. Dr Simes reports that his institution has received research grants from Bristol-Myers Squibb. Dr Karapetis reports serving as a member of an advisory board for Merck Serono. Dr Bardelli reports that he owns stock in and has received consultancy fees from Horizon Discovery. Dr Tejpar reports receiving research grants from Merck Serono. No other disclosures were reported.
Funding/Support: Dr De Roock is supported by a PhD grant from the Institute for the Promotion of Innovation Through Science and Technology in Flanders (IWT-Vlaanderen). Drs Sartore-Bianchi and Siena are supported by Associazione Italiana Ricerca Cancro and Oncologia Ca’Granda Onlus Fondazione. Drs Van Cutsem and Tejpar are senior clinical investigators for the Fund for Scientific Research, Flanders and received research grants from the Belgian Federation Against Cancer. Dr Bardelli is supported by the Italian Association for Cancer Research and the Italian Ministry of University and Research.
Role of the Sponsor: The funding sources had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Additional Contributions: We acknowledge Jef De Schutter, MSc, and Bart Biesmans, MSc, Digestive Oncology Unit, University Hospital Gasthuisberg, for laboratory analysis support, and Nancy Gustafson, MS, Daniel Malone, BS, and Christopher T. Harbison, PhD, Bristol-Myers Squibb, for laboratory and statistical analysis support. They did not receive compensation for their work.
This article was corrected for a funding/support omission on December 13, 2010.